On Sept. 8, 2021, Novavax announced enrollment of the first participants in a Phase 1/2 study to evaluate the safety and immunogenicity of a combination vaccine using Novavax’s seasonal influenza and COVID-19 vaccines.

The clinical trial combined Novavax’s recombinant protein-based NVX-CoV2373 and NanoFlu vaccine candidates and patented saponin-based Matrix-M adjuvant in a single formulation (COVID-NanoFlu Combination Vaccine). Both NVX-CoV2373 and NanoFlu previously demonstrated strong results as standalone vaccines in Phase 3 clinical trials.